These findings not only establish PSD3 as a potential biomarker and therapeutic target in ESCC but also provide mechanistic insight into how immune checkpoint dynamics may be modulated by less-characterized oncogenic drivers. The gene discussed is PSD3; the disease is esophageal squamous cell carcinoma.